Regenerative and stem cell therapy practices part 19

Stem cell 2


Until recently, the regulatory landscape for stem cell and regenerative therapies has been at times restrictive, allowing patients to access stem cell interventions only under the Expanded Access to Investigational Drugs for Treatment Use program. Treatments are eligible under this program if they are undergoing  testing a clinical trial and are subject to approval by the FDA. Three-quarters of the states in the nation have passed “Right to Try” legislation, however, which allows terminally ill patients to receive experimental therapies that have passed 1 trials without seeking FDA approval.

About azaleaazelia

A nice person... :)
This entry was posted in Tak Berkategori. Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s